Oncimmune sells its diagnostic business to Freenome for £13 million
LONDON, UK: Oncimmune Holdings has sold its diagnostic business, including the EarlyCDT® Lung blood test and antibody platform, to Freenome Holdings, a US-based biotechnology company...
Oncimmune signs agreement to profile patients
LONDON, UK: Oncimmune Holdings has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in...